GSK inks deal for AI-driven drug discovery

Exscientia inked a drug discovery collaboration with GlaxoSmithKline (NYSE:GSK) that could bring the Scotland-based company up to $37.5 million.

As a part of the deal, Exscientia plans to use its artificial-intelligence platform to discover small molecules for up to 10 disease-related targets, as chosen by GSK.

Get the full story at our sister site, Drug Delivery Business News.

The post GSK inks deal for AI-driven drug discovery appeared first on MassDevice.

from MassDevice http://ift.tt/2tJUusB